AU3268500A - Pharmaceutical compositions comprising metal complexes - Google Patents

Pharmaceutical compositions comprising metal complexes Download PDF

Info

Publication number
AU3268500A
AU3268500A AU32685/00A AU3268500A AU3268500A AU 3268500 A AU3268500 A AU 3268500A AU 32685/00 A AU32685/00 A AU 32685/00A AU 3268500 A AU3268500 A AU 3268500A AU 3268500 A AU3268500 A AU 3268500A
Authority
AU
Australia
Prior art keywords
ruthenium
bis
amd
iii
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU32685/00A
Other languages
English (en)
Inventor
Michael J. Abrams
Ian Baird
Gary Bridger
Beth R. Cameron
Simon Fricker
Renato Skerlj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anormed Inc
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Publication of AU3268500A publication Critical patent/AU3268500A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0046—Ruthenium compounds
    • C07F15/0053—Ruthenium compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU32685/00A 1999-03-19 2000-03-17 Pharmaceutical compositions comprising metal complexes Abandoned AU3268500A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12516699P 1999-03-19 1999-03-19
US60125166 1999-03-19
PCT/CA2000/000294 WO2000056743A1 (en) 1999-03-19 2000-03-17 Pharmaceutical compositions comprising metal complexes

Publications (1)

Publication Number Publication Date
AU3268500A true AU3268500A (en) 2000-10-09

Family

ID=22418482

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32685/00A Abandoned AU3268500A (en) 1999-03-19 2000-03-17 Pharmaceutical compositions comprising metal complexes

Country Status (15)

Country Link
US (1) US20020049190A1 (enExample)
EP (1) EP1163247A1 (enExample)
JP (1) JP2004500321A (enExample)
KR (1) KR20010112343A (enExample)
CN (1) CN1391577A (enExample)
AU (1) AU3268500A (enExample)
BR (1) BR0011678A (enExample)
CA (1) CA2367282A1 (enExample)
CZ (1) CZ20013307A3 (enExample)
HU (1) HUP0400457A2 (enExample)
IL (1) IL145290A0 (enExample)
MX (1) MXPA01009410A (enExample)
NO (1) NO20014526L (enExample)
PL (1) PL356683A1 (enExample)
WO (1) WO2000056743A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1165576T3 (da) 1999-04-13 2006-03-27 Anormed Inc Fremgangsmåde til fremstilling af amin-platin-komplekser
JP4227701B2 (ja) * 1999-05-25 2009-02-18 中部キレスト株式会社 ジエチレントリアミン五酢酸ルテニウム二アンモニウム塩またはその水和物およびその製法
US6489638B2 (en) * 2000-06-23 2002-12-03 Semiconductor Energy Laboratory Co., Ltd. Light emitting device
US6894049B1 (en) 2000-10-04 2005-05-17 Anormed, Inc. Platinum complexes as antitumor agents
US20020072512A1 (en) * 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
EP2319518A1 (en) * 2002-02-04 2011-05-11 ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. Use of CO-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
GB2395431A (en) * 2002-11-20 2004-05-26 Northwick Park Inst For Medica Combination of a metal carbonyl compound and a guanylate cyclase stimulant or stabilizer for the therapeutic delivery of carbon monoxide
ES2390457T3 (es) * 2003-08-04 2012-11-13 Johnson & Johnson Consumer Companies, Inc. Métodos para el tratamiento de enfermedades dermatológicas
ATE537141T1 (de) * 2004-02-05 2011-12-15 Kyorin Seiyaku Kk Bicycloesterderivat
FR2873037B1 (fr) 2004-07-13 2008-04-11 Univ Pasteur Methodes et compositions pour le traitement de cancers
CA2631389A1 (en) * 2005-12-21 2007-06-28 Oxford Biosensors Limited Redox mediators
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
US7915427B2 (en) 2006-03-08 2011-03-29 Kyorin Pharmaceuticals Co., Ltd. Process for producing aminoacetyl pyrrolidine carbonitrile derivative and intermediate for production thereof
CA2655933C (en) 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
WO2008038305A2 (en) * 2006-09-26 2008-04-03 Jegannathan Srinivas Therapeutical formulation comprising a thiazolidinedione and a nitric oxide scavenger.
JPWO2008114857A1 (ja) 2007-03-22 2010-07-08 杏林製薬株式会社 アミノアセチルピロリジンカルボニトリル誘導体の製造方法
CN104829714A (zh) 2008-11-03 2015-08-12 阿莱斯亚生物疗法股份有限公司 特异性地阻滞肿瘤抗原的生物活性的抗体
DE102010014412A1 (de) 2010-04-08 2012-04-19 Friedrich-Schiller-Universität Jena Verwendung von zweikernigen Eisenkomplexen mit schwefelhaltigen Liganden als pharmakologische Wirkstoffe
DE102010014411A1 (de) 2010-04-08 2011-10-13 Friedrich-Schiller-Universität Jena Kohlenmonoxid und Eisen freisetzende Moleküle, deren Verwendung und Verfahren zu deren Herstellung
CA2893376A1 (en) 2011-03-31 2012-10-04 Alethia Biotherapeutics Inc. Antibodies against kidney associated antigen 1 and antigen binding fragemnts thereof
PT2699242T (pt) 2011-04-19 2018-01-22 Alfama Inc Moléculas de libertação de monóxido de carbono e utilizações das mesmas
ES2628634T3 (es) 2011-07-21 2017-08-03 Alfama, Inc. Moléculas liberadoras de monóxido de carbono-rutenio y usos de las mismas
AU2013209234B2 (en) 2012-01-09 2017-11-09 Adc Therapeutics Sa Method for treating breast cancer
DE102012004132A1 (de) 2012-02-29 2013-08-29 Friedrich-Schiller-Universität Jena Kohlenstoffmonoxid freisetzende Materialien und deren Verwendung
DE102014008537A1 (de) 2014-06-04 2015-12-17 Friedrich-Schiller-Universität Jena Wasserlösliche manganbasierte Kohlenstoffmonoxid freisetzende Moleküle, deren Verwendung und Verfahren zu deren Herstellung
WO2016065435A2 (en) * 2014-10-30 2016-05-06 Katholieke Universiteit Leuven Methods for low temperature fluorine-18 radiolabeling of biomolecules
CN113429456B (zh) * 2021-06-11 2022-05-31 首都医科大学 多肽衍生物钌类络合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721669A (en) * 1985-01-18 1988-01-26 The Trustees Of Columbia University In The City Of New York Chemical probes for left-handed DNA and chiral metal complexes as Z-specific anti-tumor agents
US5112974A (en) * 1985-01-18 1992-05-12 The Trustees Of Columbia University In The City Of New York Mixed ligand complexes and uses thereof as binding agents to DNA
GB9317686D0 (en) * 1993-08-25 1993-10-13 Johnson Matthey Plc Pharmaceutical compositions
SE9703396D0 (sv) * 1997-09-19 1997-09-19 Lincoln Binuclear complex

Also Published As

Publication number Publication date
WO2000056743A1 (en) 2000-09-28
IL145290A0 (en) 2002-06-30
HUP0400457A2 (hu) 2004-05-28
BR0011678A (pt) 2002-02-26
CZ20013307A3 (cs) 2002-05-15
MXPA01009410A (es) 2003-06-06
CN1391577A (zh) 2003-01-15
CA2367282A1 (en) 2000-09-28
US20020049190A1 (en) 2002-04-25
NO20014526D0 (no) 2001-09-18
PL356683A1 (en) 2004-06-28
JP2004500321A (ja) 2004-01-08
NO20014526L (no) 2001-10-16
EP1163247A1 (en) 2001-12-19
KR20010112343A (ko) 2001-12-20

Similar Documents

Publication Publication Date Title
US20020049190A1 (en) Pharmaceutical compositions comprising metal complexes
US6417182B1 (en) Pharmaceutical compositions comprising metal complexes
US5824673A (en) Pharmaceutical compositions comprising metal complexes
Zobi et al. CO releasing properties and cytoprotective effect of cis-trans-[ReII (CO) 2Br2L2] n complexes
Paul et al. Investigation of the reactivity between a ruthenium hexacationic prism and biological ligands
US6284752B1 (en) Pharmaceutical compositions comprising metal complexes
Lovison et al. Cationic carboxylate and thioacetate ruthenium (II) complexes: synthesis and cytotoxic activity against anaplastic thyroid cancer cells
Riedl et al. N-and S-donor leaving groups in triazole-based ruthena (ii) cycles: potent anticancer activity, selective activation, and mode of action studies
Gaspari et al. Improving Cytotoxicity against Breast Cancer Cells by Using Mixed-Ligand Ruthenium (II) Complexes of 2, 2'-Bipyridine, Amino Acid, and Nitric Oxide Derivatives as Potential Anticancer Agents
Qu et al. Sterically demanding methoxy and methyl groups in ruthenium complexes lead to enhanced quantum yields for blue light triggered photodissociation
Lu et al. Increasing the cytotoxicity of Ru (II) polypyridyl complexes by tuning the electron-donating ability of 1, 10-phenanthroline ligands
CA2418410A1 (en) Novel, water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases
USRE35458E (en) Process to obtain new mixed copper aminoacidate complexes from phenylate phenathrolines to be used as anticancerigenic agents
Ősz et al. Copper (II), nickel (II) and zinc (II) complexes of amino acids containing bis (imidazol-2-yl) methyl residues
CA2552916C (en) Metal complexes having vitamin b12 as a ligand
Yang et al. Synthesis and in vitro antitumor activity of novel iridium (III) complexes with enantiopure C2-symmetrical vicinal diamine ligands
Shoukry et al. Equilibrium studies of mixed ligand complexes involving (1, 2-diaminopropane)-palladium (II) and some bioligands
Bartolucci et al. Five-coordinate platinum (II) complexes containing substituted olefins: synthesis and cytostatic activity
Radanovic et al. Synthesis and characterization of hexadentate cobalt (III) complexes with novel edta-type ligands. 1. Circular dichroism of a cobalt (III) complex of ethylenediamine-N-acetic-N, N', N'-tri-3-propionic acid
Chou et al. Dinuclear copper (II) complexes incorporating a new pyrazolo-based sulfur-containing binucleating ligand
CA2896983A1 (en) Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
Meiske et al. Synthesis and spectral characterization of the mixed-ligand complexes [N-(2-pyridylmethyl)-L-aspartato][amino acidato] cobalt (III), Co (PLASP)(AA)
AU597932B2 (en) (Gem-heterocyclodimethanamine-N,N') platinum complexes
Savić et al. The New Ruthenium (Ii)-Bipyridyl Complex with O, O'-Diethyl-(S, S) Ethylenediamine-N, N'-Di-2-(3-Cyclohexyl) Propanoate: Synthesis and Characterization
Romani Emerging metal-organic anticancer compounds: synthesis and biological activity of novel Ga (III) and Ru (II) complexes

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 15, NO 2, PAGE(S) 350-353 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN PLEASE DELETE ALL REFERENCE TO APPLICATION NO. 32685/00